Skip to contentN
Northwest Biotherapeutics Inc
N
NWBONorthwest Biotherapeutics Inc Q3 2015 · 10-Q
Revenue$291.00K$291.00K−50.0% vs Q3 2014 Net Income$22.62M$22.62MN/M vs Q3 2014 EPS Diluted$0.25$0.25N/M vs Q3 2014 Operating Income-$13,213,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Northwest Biotherapeutics Inc · CIK 1072379 · Engraved from SEC EDGAR
Free Cash Flowderived-$13,792,000N/M Margins · derivedOperating margin-4540.5%+31.3 pt vs Q3 2014
Net margin7771.5%+11387.1 pt vs Q3 2014
ended Sep 30, 2015 · filed Nov 9, 2015 · 40 d after period end